PLoS ONE · 2013 · 44 citations · 32 references
Life SciencesMolecular BiologyOncologyEpigeneticsGene ExpressionTranscriptional RegulationCancer Cell SignalingCancer EpigeneticsCancer TranscriptomicsEpigenetic Regulation In CancerMicrorna-mediated RegulationTumor Suppressor GenesAcute LeukemiasAcute Myeloid Leukemia BiologyEpigenetic MarksMicrorna EpigeneticsMicrorna In CancerMicrorna ModulationMolecular Prognostic MarkersPrognostic Tumor Markers
Over the past years BARD1 (BRCA1-associated RING domain 1) has been considered as both a BRCA1 (BReast Cancer susceptibility gene 1, early onset) interactor and tumor suppressor gene mutated in breast and ovarian cancers. Despite its role as a stable heterodimer with BRCA1, increasing evidence indicates that BARD1 also has BRCA1-independent oncogenic functions. Here, we investigate BARD1 expression and function in human acute myeloid leukemias and its modulation by epigenetic mechanism(s) and microRNAs. We show that the HDACi (histone deacetylase inhibitor) Vorinostat reduces BARD1 mRNA levels by increasing miR-19a and miR-19b expression levels. Moreover, we identify a specific BARD1 isoform, which might act as tumor diagnostic and prognostic markers.
32
A ceRNA Hypothesis: The Rosetta Stone of a Hidden RNA Language?
Leonardo Salmena, Laura Poliseno, Yvonne Tay et al. · Cell · 2011 · 7.7K citations · Full text
MicroRNA Targeting Specificity in Mammals: Determinants beyond Seed Pairing
Andrew Grimson, Kyle Kai‐How Farh, Wendy K. Johnston et al. · Molecular Cell · 2007 · 3.8K citations · Full text
Roberto R. Rosato, Jorge A. Almenara, Steven Grant · PubMed · 2003 · 470 citations
Medicine, Oncology, Pharmacology +17